Kieran O'Kane - Feb 10, 2025 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
Chief Commercial Officer
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane
Stock symbol
BDSX
Transactions as of
Feb 10, 2025
Transactions value $
-$16,198
Form type
4
Date filed
2/12/2025, 05:11 PM
Previous filing
Nov 13, 2024
Next filing
Feb 26, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDSX Common Stock Options Exercise +48.1K +49.38% 146K Feb 10, 2025 Direct F1
transaction BDSX Common Stock Sale -$16.2K -17.5K -12.04% $0.92 128K Feb 11, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Restricted Stock Units Options Exercise $0 -1.49K -19.99% $0.00 5.96K Feb 10, 2025 Common Stock 1.49K Direct F1, F4
transaction BDSX Restricted Stock Units Options Exercise $0 -30.5K -33.33% $0.00 61.1K Feb 10, 2025 Common Stock 30.5K Direct F1, F5
transaction BDSX Restricted Stock Units Options Exercise $0 -16.1K -25% $0.00 48.3K Feb 10, 2025 Common Stock 16.1K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
F3 The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.9536, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F5 These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F6 These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.